Budipine: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Budipine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
No edit summary |
||
Line 1: | Line 1: | ||
{{ | {{Drugbox | ||
| IUPAC_name | | verifiedrevid = 437186133 | ||
| image | | IUPAC_name = 1-tert-butyl-4,4-diphenylpiperidine<ref>Martndale: The Complete Drug Reference, 35th Ed.</ref> | ||
| CAS_number | | image = Budipine.svg | ||
| ATC_prefix | |||
| ATC_suffix | <!--Clinical data--> | ||
| PubChem | | tradename = | ||
| DrugBank | | Drugs.com = {{drugs.com|international|budipine}} | ||
| | | pregnancy_category = | ||
| | | legal_status = | ||
| | | routes_of_administration = | ||
| | |||
| | <!--Pharmacokinetic data--> | ||
| | | bioavailability = | ||
| | | protein_bound = | ||
| | | metabolism = | ||
| | | elimination_half-life = | ||
| | | excretion = | ||
| | |||
<!--Identifiers--> | |||
| | | CAS_number_Ref = {{cascite|correct|??}} | ||
| CAS_number = 57982-78-2 | |||
| | | ATC_prefix = N04 | ||
| | | ATC_suffix = BX03 | ||
| PubChem = 68778 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| DrugBank = | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 62021 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = L9026OPI2Z | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D07306 | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 334491 | |||
<!--Chemical data--> | |||
| C=21 | H=27 | N=1 | |||
| molecular_weight = 293.446 g/mol | |||
| smiles = c1(ccccc1)C3(c2ccccc2)CCN(C(C)(C)C)CC3 | |||
| InChI = 1/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3 | |||
| InChIKey = QIHLUZAFSSMXHQ-UHFFFAOYAT | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3 | |||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChIKey = QIHLUZAFSSMXHQ-UHFFFAOYSA-N | |||
}} | }} | ||
'''Budipine''' is | |||
'''Budipine''' is an [[antiparkinson agent]]. | |||
Its [[mechanism of action]] is not well characterized.<ref name="pmid16784759">{{cite journal |author=Reichmann H |title=Budipine in Parkinson's tremor |journal=J. Neurol. Sci. |volume=248 |issue=1-2 |pages=53–5 |date=October 2006 |pmid=16784759 |doi=10.1016/j.jns.2006.05.039 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-510X(06)00235-8}}</ref> It is believed to be an [[NMDA receptor antagonist]],<ref>J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048</ref> however, promoting the synthesis of [[dopamine]].<ref name="url">{{cite web |url=http://www.umm.edu/patiented/articles/what_other_drugs_used_parkinsons_disease_000051_8.htm |title=umm.edu |format= |work= |accessdate=}}</ref> | |||
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.<ref name="pmid12020263">{{cite journal |author=Przuntek H, Bittkau S, Bliesath H, ''et al.'' |title=Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen |journal=Arch. Neurol. |volume=59 |issue=5 |pages=803–6 |date=May 2002 |pmid=12020263 |doi= 10.1001/archneur.59.5.803|url=http://archneur.ama-assn.org/cgi/pmidlookup?view=long&pmid=12020263}}</ref> | |||
==See also== | ==See also== | ||
* [[Piperidine]] | * [[Piperidine]] | ||
{{ | ==References== | ||
{{Reflist|2}} | |||
{{Antiparkinson}} | |||
{{Glutamatergics}} | |||
[[Category:Antiparkinsonian agents]] | [[Category:Antiparkinsonian agents]] | ||
[[Category:Piperidines]] | |||
{{ | {{nervous-system-drug-stub}} |
Revision as of 13:41, 10 April 2015
File:Budipine.svg | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C21H27N |
Molar mass | 293.446 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
Budipine is an antiparkinson agent.
Its mechanism of action is not well characterized.[2] It is believed to be an NMDA receptor antagonist,[3] however, promoting the synthesis of dopamine.[4]
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[5]
See also
References
- ↑ Martndale: The Complete Drug Reference, 35th Ed.
- ↑ Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
- ↑ J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
- ↑ "umm.edu".
- ↑ Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.
Categories:
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Antiparkinsonian agents
- Piperidines